New data on Molecular Partners’ radiotherapy candidate MP0712 shows targeted delivery into cancer tumours. MP0712 is being developed for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. The candidate, which targets DLL3, showed potential to deliver radiotherapy treatment to tumours with… Read More
Researchers from the Francis Crick Institute have found that aggressive lung cancer cells can develop their own electric network, like that seen in the nervous system. This unique property could make them less dependent on the environment surrounding the tumour and even spread more easily, say the… Read More
Roche and Innovent Biologics have agreed a collaboration and exclusive license agreement to develop antibody drug conjugate (ADC) IBI3009 for advanced small cell lung cancer. Under the agreement, the two parties will jointly focus on the early-stage development of the ADC candidate, after which Roche will take over full development. … Read More
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has dosed the first patient with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC), at the Murdoch University Health Center in Perth, Australia. Ariceum has… Read More
